Bli medlem
Bli medlem

Du är här

2016-02-02

Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference

Annual BIO CEO & Investor Conference

SAN DIEGO, 2016-02-02 13:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing
innovative medicines in urology and rheumatology, today announced that Richard
Pascoe, Chief Executive Officer, will present at the 18th Annual BIO CEO &
Investor Conference on Monday, February 8, 2016, at 9:30 a.m. Eastern Time.
The conference will be held at The Waldorf Astoria, New York, NY. Mr. Pascoe
will provide an update on Vitaros®, the Company's topical treatment for
erectile dysfunction, as well as Apricus' drug candidates fispemifene, for the
treatment of men with secondary hypogonadism and RayVa™, for the treatment of
patients with Raynaud's phenomenon.

A live audio webcast of the presentation can be accessed via the Investor
Relations section of the Company's website at www.apricusbio.com. Please log in
approximately 5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus recently completed
enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor
modulator for the treatment of symptomatic male secondary hypogonadism, and
plans to conduct additional studies in other urological conditions. Apricus has
completed a Phase 2a trial for RayVa™, its product candidate for the treatment
of the circulatory disorder Raynaud's phenomenon, and plans to conduct
additional clinical trials in patients with Raynaud's phenomenon secondary to
scleroderma. Apricus' lead commercial product, Vitaros®, for the treatment of
erectile dysfunction, is approved in Europe and Canada and is being
commercialized in several countries in Europe. Apricus recently in-licensed the
U.S. development and commercialization rights for Vitaros from Allergan.
Apricus' marketing partners for Vitaros include Laboratoires Majorelle, Bracco
S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati
Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring
Pharmaceuticals) and Mylan NV. Apricus' second-generation room temperature
Vitaros is currently under development.

For further information on Apricus, visit http://www.apricusbio.com.

CONTACT: Institutional / Retail Investors: Matthew Beck
mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.